



Albireo to Present at Cantor Fitzgerald Global Healthcare Conference

September 24, 2018

BOSTON, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Dr. Patrick Horn, Chief Medical Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay in New York City on October 2 at 4:35 p.m.

The company also will participate in the Roth NASH Conference in New York on October 17, the William Blair Liver Conference in San Francisco on November 13, and the Jefferies 2018 London Healthcare Conference in London on November 14-15.

About Albireo

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo's clinical pipeline also includes two Phase 2 product candidates. Albireo's elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact:

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568

Media Contact:

Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com

Source: Albireo Pharma, Inc.



Source: Albireo Pharma, Inc.